Business Context and Reporting Period
Company: Mind Medicine (MindMed) Inc. (Note: Request metadata listed "Definium Therapeutics, Inc." but the filing text identifies Mind Medicine).
Filing Type: Form 8-K (Current Report)
Date of Report: October 29, 2025
Reporting Period: The filing discloses preliminary financial information as of September 30, 2025, in connection with a prospectus supplement and updated corporate presentation.
Key Financial Metrics
Liquidity: The Company reported estimated preliminary cash, cash equivalents, and investments of approximately $209.1 million as of September 30, 2025.
Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
Debt: The filing text does not provide specific values for outstanding debt or leverage ratios.
Audit Status: The financial information is unaudited, preliminary, and subject to completion. KPMG LLP has not audited, reviewed, or expressed an opinion on these figures.
Material Changes
The filing does not provide comparative data against prior periods to quantify material changes in financial performance. The primary disclosure is the update of the Company's estimated cash position as of September 30, 2025.
Outlook, Risks, and Management Commentary
Management Commentary: Management prepared the preliminary cash estimates based on currently available information. The figures are included in a Prospectus Supplement and a corporate presentation posted on October 29, 2025.
Risks and Contingencies: The filing explicitly states that the preliminary financial information may vary from the Company's actual financial position. It is possible that the Company or its independent auditors may identify items requiring adjustments to the reported figures.
Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and investment balances once the audit is complete, as the $209.1 million figure is preliminary.
- Review the attached Exhibit 99.1 (Corporate Presentation) for additional context on the Company's strategic outlook and capital allocation.
- Confirm the status of the prospectus supplement referenced in Item 2.02 to understand the context of the capital raise or offering.
- Monitor future filings for the final audited financial statements to reconcile any adjustments to the preliminary September 30, 2025, figures.